Adeno associated vector-based gene therapy strategy for type 3 glycogen storage disease
Pierre Vidal(University of Reunion Island), Federico Mingozzi(Spark Therapeutics (United States)), Séverine Charles(Inserm), Laetitia van Wittenberghe(Genethon (France)), Alban Vignaud(Genethon (France)), Helena Costa Verdera(Spark Therapeutics (United States)), Gıancarlo Comı(Casa di Cura Columbus), Fabienne Rajas(Université Claude Bernard Lyon 1), Fanny Collaud(Inserm), Giuseppe Ronzitti(Inserm), Bernard Gjata(Inserm), P. Collela(Genethon (France)), Marcelo Simon Sola(Inserm), Francesco Puzzo(Inserm), Edoardo Malfatti(Hôpitaux Universitaires Henri-Mondor), Pascal Laforêt(Institut de Myologie), Monika Gjorgjieva(Lyon 1 Université)
Cited by 1
Related Papers
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
|Multiple Sclerosis Journal|2018|706
Ofatumumab versus Teriflunomide in Multiple Sclerosis
|New England Journal of Medicine|2020|706
Multiple sclerosis progression: time for a new mechanism-driven framework
|The Lancet Neurology|2022|624